Early versus delayed or no empagliflozin initiation after hospitalisation for heart failure in the United States: A target trial emulation
Abstract
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a foundational therapy for heart failure (HF), yet initiation is frequently delayed in clinical practice. Evidence comparing outcomes associated with early versus delayed or no initiation following hospitalisation for heart failure (HHF) remains limited.
Methods: This retrospective cohort study used the Optum de-identified Clinformatics Data Mart and included adults hospitalised for HF between September 2021 and December 2023. A target trial emulation using the clone-censor-weight approach compared patients according to the timing of empagliflozin initiation: during HHF or within 0-7 days post-discharge (early), 8-91 days post-discharge (intermediate), and 92-365 days post-discharge or no initiation within 1 year of discharge (delayed or no initiation). Outcomes assessed during the first year after discharge included all-cause mortality, worsening HF events, and all-cause hospitalisations. Health care resource utilisation (HCRU) was assessed using landmark analyses at Days 7 and 91 post-discharge.
Results: Among 99,738 eligible patients (mean age [standard deviation] 78.0 [9.2] years; 54.2% female), early and intermediate empagliflozin initiation were associated with lower 1-year post-discharge all-cause mortality than delayed or no initiation (risk ratio [RR] 0.73, 95% confidence interval [CI]: 0.69-0.78; and RR 0.93, 95% CI: 0.89-0.97, respectively). Further, 1-year absolute mortality risk was 24.7% with…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 99,738 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.